How Aurion Biotech is Accelerating Single-Cell RNA-Seq Analysis with their Mithrl AI Co-Scientist

When every week matters in drug discovery, slow bioinformatics can mean missed opportunities. Aurion Biotech, a leader in advanced cell therapy development, faced that challenge head-on. By adopting Mithrl’s AI-powered platform, Aurion dramatically cut analysis timelines while expanding access to critical insights across their team.

From Bottleneck to Breakthrough

Single-cell RNA sequencing (scRNA-seq) is a cornerstone of modern cell therapy research. It guides target discovery, biomarker identification, and even intellectual property (IP) development. But the traditional bioinformatics workflows Aurion relied on were hitting roadblocks:

• Slow cycles: Complex scRNA-seq studies took 8–10 weeks to analyze.
• Limited access: Only expert bioinformaticians could run the workflows, leaving scientists and executives waiting for answers.

Aurion needed a faster, more accessible path from raw data to actionable insight.

Enter Mithrl

Mithrl’s AI platform, designed as a conversational “Co-Scientist,” combines advanced single-cell analytics with a natural language interface. That means researchers can type a question, in natural language, and receive rapid, rigorous results without coding or pipeline management.

Aurion tasked their Mithrl Co-Scientist to work on:

• Identifying subpopulations within cell therapy products.
• Tracking cell populations longitudinally to ensure therapeutic stability.
• Integrating scRNA-seq data with bulk RNA-seq and public datasets.
• Generating IP-ready insights through high-confidence gene targets.

The impact was immediate.

“We have identified novel IP using results generated from the Mithrl platform. That tells you how confident we feel about the insights. We rely on Mithrl for all our analyses!”
— Chief Executive Officer, Aurion Biotech

The Results

⏱ Radical Time Savings

Aurion cut analysis timelines from two months to one week, enabling faster decision-making in R&D and IP strategy.

“We gave the same dataset to both a human bioinformatician and Mithrl. The human took over two months, while Mithrl delivered the exact same insights in less than a week, and also helped drive our decision-making process.”
— Director of Therapeutics Delivery, Aurion Biotech

👩‍🔬 Accessible and Collaborative Bioinformatics

Mithrl’s natural language interface empowered wet lab scientists, project managers, and executives to run analyses themselves. Adoption spread quickly thanks to its clean, intuitive design.

✅ High Confidence in Results

• High overlap in target identification with human bioinformaticians.
• Built-in QA/QC workflows.

📜 IP Generation

Aurion used Mithrl to help identify novel, high-confidence targets suitable for patent protection, strengthening its competitive edge.

Looking Ahead

Aurion continues to expand its use of Mithrl, benefiting from rapid product rollouts often delivered within just 3–7 days of request. Together, the partnership demonstrates how AI-powered bioinformatics can unlock speed, discovery potential, and accessibility — helping biotech companies turn data into breakthroughs faster than ever.

✨ Want to see how Mithrl can transform your biopharma R&D discovery from single-cell or bulk RNA-Seq data?    Request a Demo